Ultragenyx Pharmaceutical Inc. (LON:0LIF)
39.50
+2.88 (7.86%)
At close: Jul 2, 2025
Ultragenyx Pharmaceutical Revenue
Ultragenyx Pharmaceutical had revenue of $139.29M USD in the quarter ending March 31, 2025, with 27.99% growth. This brings the company's revenue in the last twelve months to $590.69M, up 33.46% year-over-year. In the year 2024, Ultragenyx Pharmaceutical had annual revenue of $560.23M with 29.01% growth.
Revenue (ttm)
$590.69M
Revenue Growth
+33.46%
P/S Ratio
6.03
Revenue / Employee
$456.48K
Employees
1,294
Market Cap
2.76B GBP
Revenue Chart
* This company reports financials in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 560.23M | 125.98M | 29.01% |
Dec 31, 2023 | 434.25M | 70.92M | 19.52% |
Dec 31, 2022 | 363.33M | 11.92M | 3.39% |
Dec 31, 2021 | 351.41M | 80.38M | 29.66% |
Dec 31, 2020 | 271.03M | 167.32M | 161.32% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
AstraZeneca | 42.56B |
Shell | 217.54B |
HSBC Holdings | 44.89B |
Unilever | 50.25B |
Rolls-Royce Holdings | 18.91B |
British American Tobacco p.l.c. | 25.87B |
Rio Tinto Group | 42.86B |
RELX PLC | 9.43B |